Evaluation of the safety profile of an electronic vapour product used for two years by smokers in a real-life setting.
There were no safety concerns in smokers using an EVP for 2 years. Headache, nasopharyngitis and sore throat were the most common adverse events in smokers using an EVP, declining over time. The frequency of adverse events steadily decreased over time after switching to an EVP. EVP use was associated with a reduction in cigarette consumption and a reduced exposure to cigarette smoke constituents. Use of the EVP did not lead to clinically significant adverse changes in biomarkers of haematology or lipid metabolism.
Study funded by Fontem
Regulatory Toxicology and Pharmacology
Tanvir Walelea, Jim Bush, Annelize Koch, RebeccaSavioz, Claire Martin, Grant O'Connell
Walele T, Bush J, Koch A, Savioz R, Martin C, O’Connell G. Evaluation of the safety profile of an electronic vapour product used for two years by smokers in a real-life setting. Regul Toxicol Pharmacol 2018;92:226-38. doi:10.1016/j.yrtph.2017.12.010 pmid:29248487